

REMARKS

Reconsideration of the application is respectfully requested. Claims 34 and 35 have been amended. Claims 34-36 are pending and at issue.

Claim 34 has been amended for clarification to remove the term "Fragment" from the phrase "Fragment T," as suggested by the Examiner.

Claim 35 has been amended to indicate the point of attachment for each of the protecting groups shown in this claim. Support for this amendment is found in the specification as indicated, for example, in Table D (copy attached as Exhibit A), which was previously submitted to the U.S. Patent and Trademark Office with an Amendment filed November 3, 2003 in connection with the present application.

No new matter has been added.

Rejection Under 35 U.S.C. §112, First Paragraph

Claim 35 has been rejected under 35 U.S.C. §112, first paragraph as containing new matter. The Examiner states that the claimed protecting groups are not supported by the specification.

The rejection is respectfully traversed, and reconsideration is requested.

Support for each of the protecting groups recited in claim 35 is found in the specification, as indicated in Table D, which lists specific examples of support for the protected amino acid side chains. No new matter has been added. Accordingly, applicants respectfully request that this rejection be withdrawn.

Rejection Under 35 U.S.C. §112, Second Paragraph

Claims 34-36 have been rejected under 35 U.S.C. §112, second paragraph as being allegedly indefinite. According to the Examiner, the listing of protecting groups in claim 35 is

indefinite because the point of attachment on each protecting group is not clear. Additionally, the Examiner states that the phrase "Fragment T" in claim 34 is indefinite, and suggests deletion of the word "Fragment."

Claim 35 has been amended to indicate the point of attachment on each protecting group listed in this claim. Support for this amendment is found in the specification as shown in Table D. Additionally, claim 34 has been amended to remove the word "Fragment" from the phrase "Fragment T," as suggested by the Examiner. Therefore, applicants respectfully request that these rejections be withdrawn.

Conclusion

In view of the above amendments and remarks, it is respectfully requested that the application be reconsidered and that claims 34-36 be allowed and the case passed to issue.

If there are any other issues remaining, which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Dated: August 29, 2006

Respectfully submitted,












By 
Dianna Goldenson
Registration No.: 52,949
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)

Table D

Protecting Groups on Amino Acids Side Chains (W)

Substituent Group with Structure	Support in Document
 Boc	<p>Specified as part of definition of R_{61} and R_{62}, p 6, line 23, also within Claim 1. Specified in Figure 1 as part of definition of PGN where PGN_1 and PGN_2 are shown on the Arg side chain.</p> <p>Specified as part of definition of R_5, p 6, line 23, also within Claim 1, with R_5 being -COO-tBu. Specified in Figure 1 as part of definition of PGN.</p>
 Cbz	<p>Part of definition of R_{61} and R_{62}, p 6, line 23, also within Claim 1, as -COO-CH₂-Ar where Ar, the aromatic moiety, is phenyl. Specified in Figure 1 as part of definition of PGN (PGN_1 and PGN_2 are shown on the Arg side chain), where it is listed as -CO-O-Bn, with Bn being an acceptable alternative abbreviation for benzyl.</p>
 tBu	<p>Part of definition of R_5, p 6, line 23, also within Claim 1, with R_5 being -COO-CH₂-Ar with Ar, an aromatic moiety, being phenyl. Specified in Figure 1 as part of definition of PGN as -CO-O-Bn where Bn is an acceptable alternative abbreviation for benzyl.</p> <p>Specified as part of definition of R_8, p 7, line 11, also within Claim 1, with R_8 being -O-tBu. Specified in Figure 1 as part of definition of PGacid as -O-tBu.</p>
 Bzl	<p>Specified as part of definition of R_9, p 7, line 19, also within Claim 1, with R_9 being -tBu. Specified as part of definition of PGS in Figure 1.</p> <p>Part of definition of R_8, p 7, line 12, also within Claim 1, with R_8 as -O-CH₂-Ar with Ar, an aromatic moiety, being phenyl. Specified in Figure 1 as part of definition of PGacid as -O-Bn, with Bn being an acceptable alternative abbreviation for benzyl.</p>

	<p>Specified as part of definition of R₈, p 7, line 11, also within Claim 1, with R₈ being -OCH₃. Specified in Figure 1 as part of definition of PGacid as -OCH₃. Listed as part of the products obtained in Example 6, p 37.</p>
	<p>Part of definition of R₈, p 7, line 12, also within Claim 1, with R₈ as -O-CH₃ substituted with the selection of -CH₃ from the specified group presented. Part of definition of PGacid in Figure 1 with PGacid being -O-CH₃ substituted with the selection of -CH₃ from the specified group listed in the footnote.</p>
	<p>Part of definition of R₈, p 7, line 12, also within Claim 1, with R₈ being -O-CH₂-Ar with Ar, an aromatic moiety, being fluorenyl.</p>
	<p>Specifically presented within Example 1 (p 20) as well as in an Example preparation of N^ε-Boc-N^{1m}-Doc-histidine as an amino acid building block on pp 41-42.</p>
	<p>Part of definition of R₅, p 6, line 23, also within Claim 1, with R₅ being -COO-CH₂-Ar with Ar, an aromatic moiety, being fluorenyl.</p>

 <p>2-Cl-Z</p>	<p>Part of definition of R₅, p 6, line 23, also within Claim 1, with R₅ being -COO-CH₂-Ar with Ar, an aromatic moiety, being 2-chlorophenyl.</p>
--	---